<DOC>
	<DOC>NCT03007394</DOC>
	<brief_summary>The objective of this study is to evaluate the efficacy and safety of lorcaserin in the treatment of cocaine use disorder.</brief_summary>
	<brief_title>Lorcaserin in the Treatment of Cocaine Use Disorder</brief_title>
	<detailed_description>This is a 19-week, multi-center, randomized, Phase 2 clinical study comparing the efficacy of lorcaserin (10mg, b.i.d) to matched placebo in the treatment of cocaine use disorder. Up to 3 weeks will be allowed for the Screening Period and a 13-week treatment phase, with a 3-week follow-up period, with scheduled visits during Study weeks 14 and 16.</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Cocaine-Related Disorders</mesh_term>
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Cocaine</mesh_term>
	<criteria>Has a DSM5 diagnosis of current cocaine use disorder as verified by the Structured Clinical Interview for DSM5 Is seeking treatment for cocaine use disorder Is able to understand and provide written informed consent Has used cocaine on at least 1 day in the last 30 days prior to screening Has completed all psychological assessments and procedures during the screening period If female, not pregnant, lactating, unable to conceive OR must agree to use an acceptable method of birth control Has a total body weight greater than 110 pounds and body mass index greater than 20 Contact site for more information</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Cocaine Use Disorder</keyword>
</DOC>